Relationship between Polygenic Risk Score and the Hypnotics in Bipolar I Disorder
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Bipolar disorder (BD) is marked by significant change in mood and energy levels with sleep disturbance a common feature, resulting in diminished quality of life and impaired daily functioning. This study assessed the association between BD-polygenic risk scores (PRS) and hypnotics in bipolar I disorder (BD-I) patients. Methods: Large-sample data were collected from the genome-wide association study of a multicenter Bipolar Genomic Study, and 1,394 BD-I patients with available medication information were divided into two groups depending on whether they used hypnotics or not. The Diagnostic Interview for Genetic Studies (DIGS) score was used to assess the clinical manifestations and function of the participants and the association between the use of hypnotics and genetic risk was analyzed. Results: Of the 1,394 total participants, 556 (40%) patients received hypnotics, mostly benzodiazepines, administered singly or in combination with other sleeping agents such as, Z-drugs, melatonin-related drugs, and trazodone. The DIGS score was significantly higher for negative categories in the group prescribed hypnotics as was the BD-PRS score, according to the four p value thresholds (p = 0.3, 0.2, 0.1, and 0.05). Logistic regression analysis confirmed a statistically significant association between the BD-PRS and hypnotic use. Conclusion: Our results suggest an association between hypnotic use and genetic susceptibility to BD. Sleep disturbances in participants were based on the prescription status of hypnotics supporting the hypothesis that sleep disturbances may be associated with genetic aspects of BD-I. Further genetic studies on genetic overlaps between BD and specific phenotypes or medication responses are required.
Abstract
Objective: Bipolar disorder (BD) is marked by significant change in mood and energy levels with sleep disturbance a common feature, resulting in diminished quality of life and impaired daily functioning. This study assessed the association between BD-polygenic risk scores (PRS) and hypnotics in bipolar I disorder (BD-I) patients. Methods: Large-sample data were collected from the genome-wide association study of a multicenter Bipolar Genomic Study, and 1,394 BD-I patients with available medication information were divided into two groups depending on whether they used hypnotics or not. The Diagnostic Interview for Genetic Studies (DIGS) score was used to assess the clinical manifestations and function of the participants and the association between the use of hypnotics and genetic risk was analyzed. Results: Of the 1,394 total participants, 556 (40%) patients received hypnotics, mostly benzodiazepines, administered singly or in combination with other sleeping agents such as, Z-drugs, melatonin-related drugs, and trazodone. The DIGS score was significantly higher for negative categories in the group prescribed hypnotics as was the BD-PRS score, according to the four p value thresholds (p = 0.3, 0.2, 0.1, and 0.05). Logistic regression analysis confirmed a statistically significant association between the BD-PRS and hypnotic use. Conclusion: Our results suggest an association between hypnotic use and genetic susceptibility to BD. Sleep disturbances in participants were based on the prescription status of hypnotics supporting the hypothesis that sleep disturbances may be associated with genetic aspects of BD-I. Further genetic studies on genetic overlaps between BD and specific phenotypes or medication responses are required.
참고문헌 (41)
- Grande I, "Bipolar disorder", Lancet, 387, pp.1561~1572 (2016)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-5" (2013), American Psychiatric Association
- The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020, "Murray CJ", Harvard School of Public Health (Cambridge, Mass.); World Health Organization; International Bank for Reconstruction and Development, ~ (2020)
- Kaplan KA, "Sleep and sleep treatments in bipolar disorder", Curr Opin Psychol, 34, pp.117~122 (2020)
- Takaesu Y, "Circadian rhythm in bipolar disorder : a review of the literature", Psychiatry Clin Neurosci, 72, pp.673~682 (2018)
- Alloy LB, "Circadian rhythm dysregulation in bipolar spectrum disorders", Curr Psychiatry Rep, 19, pp.21~ (2017)
- Wehr TA, "Sleep reduction as a final common pathway in the genesis of mania", Am J Psychiatry, 144, pp.201~204 (1987)
- Jackson A, "A systematic review of manic and depressive prodromes", J Affect Disord, 74, pp.209~217 (2003)
- Gruber J, "Sleep functioning in relation to mood, function, and quality of life at entry to the Systematic Treatment Enhancement Program for Bipolar Disorder(STEP-BD)", J Affect Disord, 114, pp.41~49 (2009)
- Harvey AG, "Sleep-related functioning in euthymic patients with bipolar disorder, patients with insomnia, and subjects without sleep problems", Am J Psychiatry, 162, pp.50~57 (2005)
- Harvey AG, "Sleep and circadian rhythms in bipolar disorder : seeking synchrony, harmony, and regulation", Am J Psychiatry, 165, pp.820~829 (2008)
- Bradley AJ, "The association between sleep and cognitive abnormalities in bipolar disorder", Psychol Med, 50, pp.125~132 (2020)
- Sylvia LG, "Sleep disturbance may impact treatment outcome in bipolar disorder : a preliminary investigation in the context of a large comparative effectiveness trial", J Affect Disord, 225, pp.563~568 (2018)
- Craddock N, "Genetics of bipolar disorder", J Med Genet, 36, pp.585~594 (1999)
- Benedetti F, "Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression", Am J Med Genet B Neuropsychiatr Genet, 123B, pp.23~26 (2003)
- Benedetti F, "A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder", Neurosci Lett, 355, pp.37~40 (2004)
- Ferguson A, "Genome-wide association study of circadian rhythmicity in 71, 500 UK biobank participants and polygenic association with mood instability", EBioMedicine, 35, pp.279~287 (2018)
- Lane JM, "Genome-wide association analyses of sleep disturbance traits identify new loci and highlight shared genetics with neuropsychiatric and metabolic traits", Nat Genet, 49, pp.274~281 (2017)
- Plante DT, "Sleep disturbance in bipolar disorder : therapeutic implications", Am J Psychiatry, 165, pp.830~843 (2008)
- Lewis CM, "Polygenic risk scores : from research tools to clinical instruments", Genome Med, 12, pp.44~ (2020)
- Khera AV, "Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations", Nat Genet, 50, pp.1219~1224 (2018)
- Frank J, "Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients", Mol Psychiatry, 20, pp.150~151 (2015)
- Li J, "Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes", Schizophr Res, 192, pp.194~204 (2018)
- Ward J, "Polygenic risk scores for major depressive disorder and neuroticism as predictors of antidepressant response : meta-analysis of three treatment cohorts", PLoS One, 13, pp.e0203896~ (2018)
- Amare AT, "Association of polygenic score for schizophrenia and HLA antigen and inflammation genes with response to lithium in bipolar affective disorder : a genome-wide association study", JAMA Psychiatry, 75, pp.65~74 (2018)
- Amare AT, "Association of polygenic score for major depression with response to lithium in patients with bipolar disorder", Mol Psychiatry, 26, pp.2457~2470 (2021)
- Melroy-Greif WE, "Genetic influences on evening preference overlap with those for bipolar disorder in a sample of Mexican Americans and American Indians", Twin Res Hum Genet, 20, pp.499~510 (2017)
- Lewis KJS, "Comparison of genetic liability for sleep traits among individuals with bipolar disorder I or II and control participants", JAMA Psychiatry, 77, pp.303~310 (2020)
- Risch N, "The future of genetic studies of complex human diseases", Science, 273, pp.1516~1517 (1996)
- Cross B, "Polygenic risk scores : an overview from bench to bedside for personalised medicine", Front Genet, 13, pp.1000667~ (2022)
- Schijven D, "Genetic cross-disorder analysis in psychiatry : from methodology to clinical utility", Br J Psychiatry, 216, pp.246~249 (2020)
- Smith EN, "Genome-wide association study of bipolar disorder in European American and African American individuals", Mol Psychiatry, 14, pp.755~763 (2009)
- Belmonte Mahon P, "Genome-wide association analysis of age at onset and psychotic symptoms in bipolar disorder", Am J Med Genet B Neuropsychiatr Genet, 156B, pp.370~378 (2011)
- Nurnberger JI Jr, "Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative", Arch Gen Psychiatry, 51, pp.849~859 (1994)
- Purcell S, "PLINK : a tool set for whole-genome association and population-based linkage analyses", Am J Hum Genet, 81, pp.559~575 (2007)
- Sylvia LG, "Sleep disturbance in euthymic bipolar patients", J Psychopharmacol, 26, pp.1108~1112 (2012)
- Park YM, "Interaction between adverse childhood experiences and polygenic risk in patients with bipolar disorder", Transl Psychiatry, 10, pp.326~ (2020)
- Etain B, "Genetics of circadian rhythms and mood spectrum disorders", Eur Neuropsychopharmacol, 21(Suppl 4), pp.S676~S682 (2011)
- Mansour HA, "Circadian genes and bipolar disorder", Ann Med, 37, pp.196~205 (2005)
- Bosch F, "Effects of lithium ions on glycogen synthase and phosphorylase in rat hepatocytes", J Biol Chem, 261, pp.16927~16931 (1986)
- Haggarty SJ, "Advances toward precision medicine for bipolar disorder : mechanisms & molecules", Mol Psychiatry, 26, pp.168~185 (2021)